Specialty Pharmacy

THOUSAND OAKS, Calif. — Amgen and Allergan on Wednesday announced their submission of a biologics license application to the Food and Drug Administration for ABP 215, a potential biosimilar of Avastin (bevacizumab). The companies said ABP 215 is the most advanced of the four oncologic biosimilars they are developing, and they believe it’s the first submission for an Avastin biosimilar. 

 

LEXINGTON, Mass. — Shire on Wednesday announced the launch of its Cuvitru (immune globulin subcutaneous (human) 20% solution). The drug, which was approved in September, is indicated to treat adult and pediatric patients aged two years and over with primary immunodeficiency — a group of more than 300 genetic disorders that prevent the immune system from functioning properly. 

 

PHOENIX, Ariz. — On the heels of its announcement that it had hired a new medical advisor, Avella Specialty Pharmacy on Monday announced that it had acquired Oncology Plus, a Tampa, Fla.-based  provider of patient-specific compounded therapies. Avella said that the acquisition would further its strategic vision to become the nation’s leading omni-site specialty pharmacy and add breadth to its compounding and oncology-focused capabilities and offerings. 

CARROLLTON, Texas — AmerisourceBergen Specialty Group recently announced that it would be building a 300,000-sq. ft. corporate campus at the Offices of Austin Ranch here, which will make it one of the largest employees in Carrollton. It will serve as AmerisourceBergen Specialty Group’s new regional headquarters. 

 

PHOENIX, Ariz. — Avella Specialty Pharmacy has added Dr. Joel V. Brill as a medical advisor, the organization announced Friday. Brill will bring more than 30 years of clinical and leadership experience, as well as expertise in value-based care and advanced payment models to the company. 

 

PITTSBURGH and BENGALURU, India — Mylan and Biocon on Tuesday announced that they had submitted a biologics license application to the Food and Drug Administration for their proposed biosimilar of Herceptin (trastuzumab). The companies believe their submission has the potential to be the first of a proposed biosimilar for the drug in the United States. 

 

SCOTTSDALE, Ariz. — McKesson Specialty Health on Thursday announced that for the eighth year running, its Reimbursement, Access & Safety Services Solution Center has been certified as a Center of Excellence by call center research and consulting organization BenchmarkPortal.